CNB Financial Corporation Announces Quarterly Dividend for Common Stock GlobeNewswire November 12, 2025 CLEARFIELD, Pa., Nov. 12, 2025 (GLOBE NEWSWIRE) — The Board of Directors of CNB Financial Corporation (Nasdaq: CCNE) declared a quarterly cash dividend of $0.18 per share of common stock payable on December 12, 2025 to common stock shareholders of record as […]
Kura Oncology to Participate in Upcoming Investor Conference GlobeNewswire November 12, 2025 SAN DIEGO, Nov. 12, 2025 (GLOBE NEWSWIRE) — Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in the following investor conference: Jefferies Global Healthcare ConferenceNovember
authID Reports Financial and Operating Results for the Third Quarter 2025 GlobeNewswire November 12, 2025 DENVER, Nov. 12, 2025 (GLOBE NEWSWIRE) — authID(R) (Nasdaq: AUID) (“authID” or the “Company”), a leading provider of biometric identity verification and authentication solutions, today reported financial and operating results for the third quarter ended September 30, 2025. Third Quarter
Decent Holding Inc. Announces Closing of US$8 Million Registered Offering of Class A Ordinary Shares and Warrants GlobeNewswire November 12, 2025 YANTAI, China, Nov. 12, 2025 (GLOBE NEWSWIRE) — Decent Holding Inc. (NASDAQ: DXST) (“Decent” or the “Company”), an established wastewater treatment services provider in China, today announced the closing of its US$8 million registered
Korro Reports Third Quarter Financial Results, Provides Updates on KRRO-110 in Alpha-1 Antitrypsin Deficiency and Additional Pipeline Programs GlobeNewswire November 12, 2025 CAMBRIDGE, Mass., Nov. 12, 2025 (GLOBE NEWSWIRE) — — KRRO-110 produced functional protein in Alpha-1 Antitrypsin Deficiency (AATD) patients — KRRO-110 did not reach projected levels of functional protein following a single administration
Silvaco Reports Third Quarter 2025 Financial Results GlobeNewswire November 12, 2025 Achieved record gross bookings of $22.8 million and record revenue of $18.7 million Initiated cost-reduction actions expected to lower annualized non-GAAP operating expenses by at least $15 million SANTA CLARA, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) — Silvaco Group, Inc. (Nasdaq: SVCO) (“Silvaco” or
Echo IQ Highlights Market Potential for EchoSolv AS Following Presentation of New Data for Severe Aortic Stenosis (AS) Presented at AHA Scientific Sessions 2025 GlobeNewswire November 12, 2025 Investigator-initiated study shows potential for EchoSolv AS to drive improved patient outcomes when used to support cardiologist in identifying severe AS particularly in women NEDA study of
Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2025 GlobeNewswire November 12, 2025 Acquired exclusive global rights to LYL273, a novel GCC-targeted CAR T-cell product candidate that has demonstrated a 67% overall response rate, an 83% disease control rate and a manageable safety profile at the highest dose level studied to
Espey Mfg. & Electronics Corp. reports first quarter results GlobeNewswire November 12, 2025 SARATOGA SPRINGS, N.Y., Nov. 12, 2025 (GLOBE NEWSWIRE) — Espey Mfg. & Electronics Corp. (NYSE American: ESP) announces results for the first three months of fiscal year 2026. Net sales for the three months ended September 30, 2025 and 2024 were $9,092,876
Fractyl Health Reports Third Quarter 2025 Results; Revita(R) Clinical Momentum Builds Toward 2026 Pivotal Readout and PMA Filing, Cash Runway Extended into Early 2027 GlobeNewswire November 12, 2025 Positive randomized 3-month REMAIN-1 Midpoint Cohort data showed single Revita procedure maintained weight loss after GLP-1 discontinuation; 6-month data expected in Q1 2026 6-month data from open-label